<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Rev Bras Ter Intensiva</journal-id><journal-id journal-id-type="iso-abbrev">Rev Bras Ter Intensiva</journal-id><journal-id journal-id-type="publisher-id">rbti</journal-id><journal-title-group><journal-title>Revista Brasileira de Terapia Intensiva</journal-title></journal-title-group><issn pub-type="ppub">0103-507X</issn><issn pub-type="epub">1982-4335</issn><publisher><publisher-name>Associa&#x000e7;&#x000e3;o de Medicina Intensiva Brasileira -
AMIB</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4943057</article-id><article-id pub-id-type="doi">10.5935/0103-507X.20160032</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Hantavirus cardiopulmonary syndrome successfully treated with
high-volume hemofiltration</article-title><trans-title-group xml:lang="pt"><trans-title>Tratamento bem-sucedido da s&#x000ed;ndrome cardiopulmonar por
hantav&#x000ed;rus com uso de hemofiltra&#x000e7;&#x000e3;o de alto
volume</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bugedo</surname><given-names>Guillermo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/></contrib><contrib contrib-type="author"><name><surname>Florez</surname><given-names>Jorge</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ferres</surname><given-names>Marcela</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Roessler</surname><given-names>Eric</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Bruhn</surname><given-names>Alejandro</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Departamento de Medicina Intensiva, Escuela de Medicina,
Pontificia Universidad Catolica de Chile - Santiago, Chile.</aff><aff id="aff2"><label>2</label>Departamento de Enfermedades Infecciosas e Inmunologia
Pedi&#x000e1;trica, Escuela de Medicina, Pontificia Universidad Catolica de Chile -
Santiago, Chile.</aff><aff id="aff3"><label>3</label>Departamento de Nefrolog&#x000ed;a, Escuela de Medicina,
Pontificia Universidad Catolica de Chile - Santiago, Chile.</aff><author-notes><corresp id="c1"><bold>Corresponding author:</bold> Guillermo Bugedo, Pontificia
Universidad Catolica de Chile Marcoleta, 367 6510260 - Santiago, Chile</corresp><fn fn-type="conflict"><p><bold>Conflicts of interest:</bold> None.</p></fn></author-notes><pub-date pub-type="epub-ppub"><season>Apr-Jun</season><year>2016</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Apr-Jun</season><year>2016</year></pub-date><volume>28</volume><issue>2</issue><fpage>190</fpage><lpage>194</lpage><history><date date-type="received"><day>20</day><month>8</month><year>2015</year></date><date date-type="accepted"><day>09</day><month>12</month><year>2015</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><p>Hantavirus cardiopulmonary syndrome has a high mortality rate, and early
connection to extracorporeal membrane oxygenation has been suggested to improve
outcomes. We report the case of a patient with demonstrated Hantavirus
cardiopulmonary syndrome and refractory shock who fulfilled the criteria for
extracorporeal membrane oxygenation and responded successfully to high volume
continuous hemofiltration. The implementation of high volume continuous
hemofiltration along with protective ventilation reversed the shock within a few
hours and may have prompted recovery. In patients with Hantavirus
cardiopulmonary syndrome, a short course of high volume continuous
hemofiltration may help differentiate patients who can be treated with
conventional intensive care unit management from those who will require more
complex therapies, such as extracorporeal membrane oxygenation.</p></abstract><trans-abstract xml:lang="pt"><p>A s&#x000ed;ndrome cardiopulmonar por hantav&#x000ed;rus tem elevada taxa de
mortalidade. Sugere-se que uma conex&#x000e3;o precoce com
oxigena&#x000e7;&#x000e3;o por membrana extracorp&#x000f3;rea melhore os
resultados. Relatamos o caso de uma paciente que apresentou s&#x000ed;ndrome
cardiopulmonar por hantav&#x000ed;rus e choque refrat&#x000e1;rio, que preenchia
os crit&#x000e9;rios para oxigena&#x000e7;&#x000e3;o por membrana
extracorp&#x000f3;rea e que teve resposta satisfat&#x000f3;ria com uso de
hemofiltra&#x000e7;&#x000e3;o cont&#x000ed;nua de alto volume. A
implanta&#x000e7;&#x000e3;o de hemofiltra&#x000e7;&#x000e3;o cont&#x000ed;nua de alto
volume, juntamente da ventila&#x000e7;&#x000e3;o protetora, reverteu o choque
dentro de poucas horas e pode ter levado &#x000e0; recupera&#x000e7;&#x000e3;o. Em
pacientes com s&#x000ed;ndrome cardiopulmonar por hantav&#x000ed;rus, um curso
r&#x000e1;pido de hemofiltra&#x000e7;&#x000e3;o cont&#x000ed;nua de alto volume pode
ajudar a diferenciar pacientes que podem ser tratados com cuidados convencionais
da unidade de terapia intensiva dos que necessitar&#x000e3;o de terapias mais
complexas, como oxigena&#x000e7;&#x000e3;o por membrana extracorp&#x000f3;rea.</p></trans-abstract><kwd-group><kwd>Sepsis</kwd><kwd>Hantavirus pulmonary syndrome/therapy</kwd><kwd>Hemofiltration/therapeutic use</kwd><kwd>Case reports</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Hantavirus cardiopulmonary syndrome (HCPS), also known as Hantavirus pulmonary
syndrome (HPS), has a 35% overall case fatality rate.<sup>(<xref rid="r1" ref-type="bibr">1</xref>)</sup> There are no specific antivirals, vaccines, or
immunotherapeutic agents for HCPS, and treatment is mainly supportive and
symptomatic.<sup>(<xref rid="r2" ref-type="bibr">2</xref>)</sup> Ribavirin
is an antiviral agent that did not yield any significant benefit in clinical
outcomes when used to treat patients during the cardiopulmonary phase of the
disease.<sup>(<xref rid="r3" ref-type="bibr">3</xref>)</sup> A recent trial
of high-dose methylprednisolone (16mg/kg/day) in patients with confirmed or
suspected HCPS, attempting to modulate the immune response responsible for the
catastrophic outcome, showed no significant clinical benefit.<sup>(<xref rid="r1" ref-type="bibr">1</xref>)</sup></p><p>Patients with HCPS and refractory shock have a particularly high mortality rate, and
early connection to extracorporeal membrane oxygenation (ECMO) has been suggested to
improve outcomes.<sup>(<xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r5" ref-type="bibr">5</xref>)</sup> However, despite an overall survival of 66%,
complications from percutaneous cannulation and bleeding are frequent with ECMO.
There has also been no prospective trial comparing ECMO with a more conservative
approach that incorporates recent advances in critical care management.<sup>(<xref rid="r6" ref-type="bibr">6</xref>)</sup> As part of our protocol for
managing patients with septic shock, high-volume continuous hemofiltration (HVHF) is
frequently used and may play a role in decreasing mortality in patients with
refractory septic shock at our institution.<sup>(<xref rid="r7" ref-type="bibr">7</xref>-<xref rid="r9" ref-type="bibr">9</xref>)</sup></p><p>We report the case of a patient with demonstrated HCPS and refractory shock who was
successfully treated with HVHF and Hantavirus hyperimmune plasma, the latter as part
of a compassionate treatment national protocol.<sup>(<xref rid="r10" ref-type="bibr">10</xref>)</sup> A short course of HVHF may help to differentiate patients
who can be treated with conventional intensive care unit (ICU) management from those
who will require more complex therapies, such as extracorporeal membrane
support.</p></sec><sec><title>CASE REPORT</title><p>A 30-year-old female patient was admitted to our emergency department in February
2013 with a six-day history of malaise and headache followed by fever. Three days
before admission, she was seen in another hospital and sent home with Levofloxacin
for suspicion of sinusitis. When symptoms worsened and she developed progressive
dyspnea, she visited our emergency department.</p><p>On admission, she had severe dyspnea and tachycardia. Laboratory results indicated a
lactate level of 4.2mmol/L, C-reactive protein of 7.7mg/dL (normal value &#x0003c; 0.5),
platelet count of 34,000/mm<sup>3</sup>, hematocrit of 47.9%, and lactate
dehydrogenase of 406U/L. Diffuse bilateral perihilar infiltrates were present on
chest radiography (<xref ref-type="fig" rid="f1">Figure 1</xref>). Troponin-T and
creatine-kinase MB were within normal limits. A blood smear showed both neutrophilia
and lymphocytosis, including lymphocytes with immunoblastic morphologic features.
Because she had recently travelled to an area with a high prevalence of Hantavirus,
a rapid test was ordered on admission, and the results were positive.</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Chest-X-ray on A) admission (left), B) the first day (center) and C) the
6<sup>th</sup> day (right) showing bilateral infiltrates suggesting
acute respiratory distress syndrome.</p></caption><graphic xlink:href="rbti-28-02-0190-g01"/></fig>
</p><p>After initial resuscitation with normal saline, she was transferred to the ICU.
Subsequently, due to poor oxygenation and severe alterations in clinical perfusion,
the patient was intubated, and protective ventilation was initiated according to our
protocol.</p><p>Despite administration of hydrocortisone 100mg and aggressive volume expansion with
normal saline and albumin, within a few hours, the patient required high dose
norepinephrine (0.7&#x000b5;g/kg/min). Peripheral perfusion was also severely altered
(lactate levels 5.9mmol/L). Echocardiography showed depressed left ventricular
function, with an estimated ejection fraction (Simpson) of 40%, in the presence of
severe tachycardia (<xref ref-type="table" rid="t1">Table 1</xref>). A pulmonary
artery catheter showed a cardiac index of 2.8L/min/m<sup>2</sup> and a stroke volume
index of 17.5mL/min/m<sup>2</sup>, confirming the diagnosis of cardiopulmonary
syndrome secondary to Hantavirus infection.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Time course of hemodynamic, clinical and laboratory variables immediately
before and after starting high volume hemofiltration</p></caption><table frame="hsides" rules="groups"><colgroup width="12%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"><bold>Time</bold></th><th align="center" rowspan="1" colspan="1"><bold>Baseline</bold></th><th align="center" rowspan="1" colspan="1"><bold>3 hours</bold></th><th align="center" rowspan="1" colspan="1"><bold>6 hours</bold></th><th align="center" rowspan="1" colspan="1"><bold>12 hours</bold></th><th align="center" rowspan="1" colspan="1"><bold>24 hours</bold></th><th align="center" rowspan="1" colspan="1"><bold>48 hours</bold></th><th align="center" rowspan="1" colspan="1"><bold>72 hours</bold></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Cardiac index (L/min/m<sup>2</sup>) </td><td align="center" rowspan="1" colspan="1">2.8</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">3.1</td><td align="center" rowspan="1" colspan="1">3.2</td><td align="center" rowspan="1" colspan="1">3.4</td><td align="center" rowspan="1" colspan="1">3.9</td><td align="center" rowspan="1" colspan="1">2.7</td></tr><tr><td rowspan="1" colspan="1">PWP (mmHg)</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">18</td></tr><tr><td rowspan="1" colspan="1">CVP (mmHg)</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">14</td></tr><tr><td rowspan="1" colspan="1">PAP (mmHg)</td><td align="center" rowspan="1" colspan="1">36/26</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">26/14</td><td align="center" rowspan="1" colspan="1">27/15</td><td align="center" rowspan="1" colspan="1">27/10</td><td align="center" rowspan="1" colspan="1">24/9</td><td align="center" rowspan="1" colspan="1">27/15</td></tr><tr><td rowspan="1" colspan="1">SVI (mL/min/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">17.5</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">24.8</td><td align="center" rowspan="1" colspan="1">25.6</td><td align="center" rowspan="1" colspan="1">25.5</td><td align="center" rowspan="1" colspan="1">35.1</td><td align="center" rowspan="1" colspan="1">27.8</td></tr><tr><td rowspan="1" colspan="1">Heart rate</td><td align="center" rowspan="1" colspan="1">160</td><td align="center" rowspan="1" colspan="1">129</td><td align="center" rowspan="1" colspan="1">125</td><td align="center" rowspan="1" colspan="1">125</td><td align="center" rowspan="1" colspan="1">133</td><td align="center" rowspan="1" colspan="1">111</td><td align="center" rowspan="1" colspan="1">97</td></tr><tr><td rowspan="1" colspan="1">Temperature (&#x000ba;C)</td><td align="center" rowspan="1" colspan="1">38.2</td><td align="center" rowspan="1" colspan="1">36.4</td><td align="center" rowspan="1" colspan="1">36.2</td><td align="center" rowspan="1" colspan="1">36.3</td><td align="center" rowspan="1" colspan="1">36.2</td><td align="center" rowspan="1" colspan="1">36.5</td><td align="center" rowspan="1" colspan="1">36.6</td></tr><tr><td rowspan="1" colspan="1">NE dose</td><td align="center" rowspan="1" colspan="1">0.7</td><td align="center" rowspan="1" colspan="1">0.42</td><td align="center" rowspan="1" colspan="1">0.16</td><td align="center" rowspan="1" colspan="1">0.11</td><td align="center" rowspan="1" colspan="1">0.04</td><td align="center" rowspan="1" colspan="1">0.1</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Fluid balance<xref ref-type="table-fn" rid="TFN4">*</xref> (L)</td><td align="center" rowspan="1" colspan="1">3.6</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">3.9</td><td align="center" rowspan="1" colspan="1">4.8</td><td align="center" rowspan="1" colspan="1">0.5</td></tr><tr><td rowspan="1" colspan="1">PaO<sub>2</sub> (mmHg)</td><td align="center" rowspan="1" colspan="1">81.2</td><td align="center" rowspan="1" colspan="1">66.7</td><td align="center" rowspan="1" colspan="1">82</td><td align="center" rowspan="1" colspan="1">86.5</td><td align="center" rowspan="1" colspan="1">88.6</td><td align="center" rowspan="1" colspan="1">115.5</td><td align="center" rowspan="1" colspan="1">89.9</td></tr><tr><td rowspan="1" colspan="1">PaCO<sub>2</sub> (mmHg)</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">31.4</td><td align="center" rowspan="1" colspan="1">26.6</td><td align="center" rowspan="1" colspan="1">33.7</td><td align="center" rowspan="1" colspan="1">38.9</td><td align="center" rowspan="1" colspan="1">32</td></tr><tr><td rowspan="1" colspan="1">pH</td><td align="center" rowspan="1" colspan="1">7.28</td><td align="center" rowspan="1" colspan="1">7.31</td><td align="center" rowspan="1" colspan="1">7.41</td><td align="center" rowspan="1" colspan="1">7.45</td><td align="center" rowspan="1" colspan="1">7.44</td><td align="center" rowspan="1" colspan="1">7.36</td><td align="center" rowspan="1" colspan="1">7.44</td></tr><tr><td rowspan="1" colspan="1">HCO<sub>3</sub> (mEq)</td><td align="center" rowspan="1" colspan="1">14.3</td><td align="center" rowspan="1" colspan="1">14.7</td><td align="center" rowspan="1" colspan="1">19.6</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">22.2</td><td align="center" rowspan="1" colspan="1">21.6</td><td align="center" rowspan="1" colspan="1">21</td></tr><tr><td rowspan="1" colspan="1">PaO<sub>2</sub>/FiO<sub>2</sub> ratio</td><td align="center" rowspan="1" colspan="1">232</td><td align="center" rowspan="1" colspan="1">148</td><td align="center" rowspan="1" colspan="1">182</td><td align="center" rowspan="1" colspan="1">216</td><td align="center" rowspan="1" colspan="1">222</td><td align="center" rowspan="1" colspan="1">289</td><td align="center" rowspan="1" colspan="1">321</td></tr><tr><td rowspan="1" colspan="1">SatmvO<sub>2</sub> (%)</td><td align="center" rowspan="1" colspan="1">74.3</td><td align="center" rowspan="1" colspan="1">62.7</td><td align="center" rowspan="1" colspan="1">67.6</td><td align="center" rowspan="1" colspan="1">63.4</td><td align="center" rowspan="1" colspan="1">66.9</td><td align="center" rowspan="1" colspan="1">79.5</td><td align="center" rowspan="1" colspan="1">54.9</td></tr><tr><td rowspan="1" colspan="1">Creatinine (mg/dL)</td><td align="center" rowspan="1" colspan="1">0.83</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">0.49</td><td align="center" rowspan="1" colspan="1">1.42</td><td align="center" rowspan="1" colspan="1">1.34</td></tr><tr><td rowspan="1" colspan="1">C-reactive protein (mg/dL) </td><td align="center" rowspan="1" colspan="1">10.6</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">14.8</td><td align="center" rowspan="1" colspan="1">7.3</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Lactate (mmol/L)</td><td align="center" rowspan="1" colspan="1">5.9</td><td align="center" rowspan="1" colspan="1">4.6</td><td align="center" rowspan="1" colspan="1">4.4</td><td align="center" rowspan="1" colspan="1">2.5</td><td align="center" rowspan="1" colspan="1">3.6</td><td align="center" rowspan="1" colspan="1">2.6</td><td align="center" rowspan="1" colspan="1">2.7</td></tr><tr><td rowspan="1" colspan="1">Albumin (g/dL)</td><td align="center" rowspan="1" colspan="1">2.6</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">2.7</td><td align="center" rowspan="1" colspan="1">2.7</td></tr><tr><td rowspan="1" colspan="1">Hematocrit (%)</td><td align="center" rowspan="1" colspan="1">40.6</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">32.1</td><td align="center" rowspan="1" colspan="1">29.7</td><td align="center" rowspan="1" colspan="1">28</td></tr><tr><td rowspan="1" colspan="1">WBC (/mm<sup>3</sup>)</td><td align="center" rowspan="1" colspan="1">23,800</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">28,000</td><td align="center" rowspan="1" colspan="1">25,100</td><td align="center" rowspan="1" colspan="1">18,500</td></tr><tr><td rowspan="1" colspan="1">Platelets (/mm<sup>3</sup>)</td><td align="center" rowspan="1" colspan="1">27,000</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">27,000</td><td align="center" rowspan="1" colspan="1">24,000</td><td align="center" rowspan="1" colspan="1">25,000</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>PWP - pulmonary artery wedge pressure; CVP - central venous pressure; PAP
- pulmonary artery pressure; SVI - stroke volume index; NE dose -
norepinephrine dose (&#x000b5;g/kg/min); PaO<sub>2</sub> - arterial
oxygen tension; PaCO<sub>2</sub> - arterial carbon dioxide tension;
HCO<sub>3</sub> - bicarbonate; PaO<sub>2</sub>/FiO<sub>2</sub> -
ratio of arterial oxygen tension to inspired oxygen fraction;
SatmvO<sub>2</sub> - mixed venous oxygen saturation; WBC - white
blood cells.</p></fn><fn id="TFN4"><label>*</label><p>Accumulated fluid balance during the previous 24 hours.</p></fn></table-wrap-foot></table-wrap><p>At that time, the ratio of arterial oxygen tension to inspired oxygen fraction
(PaO<sub>2</sub>:FiO<sub>2</sub> ratio) was approximately 200. However, due to
severe cardiac dysfunction and high norepinephrine requirements, we decided to
implement a trial of 6 hours of HVHF before deciding to initiate ECMO.</p><p>A 13.5 double-lumen catheter was inserted into the right femoral vein, and HVHF was
initiated at 100mL/kg/h. Three hours after starting HVHF, norepinephrine levels were
reduced by half, with a significant improvement in clinical perfusion. At that time,
the patient received Hantavirus hyperimmune plasma (5,000U/Kg) under a compassionate
national treatment protocol.<sup>(<xref rid="r10" ref-type="bibr">10</xref>)</sup>
Lactate levels decreased from 5.9 to 2.5mmol/L 12 hours after the initiation of HVHF
and eventually normalized a few days later. Two days later, repeat echocardiography
revealed an improvement in ejection fraction to 65% and an increase in stroke volume
index to 35mL/min/m<sup>2</sup>.</p><p>The patient continued to improve clinically, although she developed hyperactive
delirium, which was successfully managed with quetiapine and dexmedetomidine. The
patient was finally extubated 10 days after admission.</p><p>Echocardiography on day 14 showed normal systolic function, with no evidence of
pulmonary hypertension or cardiac chamber enlargement. On day 16 after admission,
she was discharged from the ICU and was sent home a few days later. Two years later,
the patient is living a normal life.</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>We describe a patient with HCPS who presented with respiratory failure and severe
cardiovascular dysfunction, fulfilling the traditional criteria for ECMO. The
implementation of HVHF may have helped to reverse shock within a few hours and,
together with conventional critical care management, may have prompted
recovery.<sup>(<xref rid="r6" ref-type="bibr">6</xref>-<xref rid="r8" ref-type="bibr">8</xref>,<xref rid="r11" ref-type="bibr">11</xref>,<xref rid="r12" ref-type="bibr">12</xref>)</sup></p><p>Hantavirus cardiopulmonary syndrome has high mortality. Treatment is mainly
supportive and symptomatic. Early connection to ECMO has been suggested to improve
outcomes in patients with HCPS and refractory shock.<sup>(<xref rid="r5" ref-type="bibr">5</xref>)</sup> In 1998, Crowley et al. identified several criteria
for non-survival, which included refractory shock, lactate &#x0003e; 4.0mmol/L, severe
hypoxia (PaO<sub>2</sub>:FiO<sub>2</sub> ratio &#x0003c; 60), and cardiac
arrest.<sup>(<xref rid="r4" ref-type="bibr">4</xref>)</sup> More recently,
Wernly et al. reported an overall survival of 66.6% in 51 patients who were treated
with ECMO support. The patients, who had at least one of the previous criteria for
non-survival, had a typical clinical presentation consistent with HCPS and a cardiac
index that rapidly dropped to &#x0003c; 2.0L/min/m2 despite maximum inotropic
support.<sup>(<xref rid="r5" ref-type="bibr">5</xref>)</sup> However, to
date, there has been no prospective trial comparing ECMO with a more conservative
approach that incorporates recent advances in critical care management, including
protective ventilation and HVHF.<sup>(<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r8" ref-type="bibr">8</xref>,<xref rid="r11" ref-type="bibr">11</xref>,<xref rid="r12" ref-type="bibr">12</xref>)</sup> Moreover, ECMO
is associated with complications derived from vessel cannulation, frequent bleeding,
and high costs.<sup>(<xref rid="r5" ref-type="bibr">5</xref>)</sup></p><p>The symptoms and severity of HCPS are mainly due to increased capillary permeability
following activation of the innate and adaptive immune response rather than direct
virus-induced cellular damage. This is likely the most important physiological
feature responsible for the massive leakage of plasma into alveoli, with resultant
pulmonary edema, in Andes virus (ANDV) infection. In experimental and some
observational trials, HVHF has been shown to remove excess inflammatory mediators
and to improve cardiopulmonary function in refractory septic shock.<sup>(<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r13" ref-type="bibr">13</xref>)</sup> However, a large randomized trial of 140 critically ill
patients with septic shock and acute kidney injury did not show a benefit of HVHF in
improving either hemodynamic profile or organ function at a dose of 70mL/kg/h
compared with 35mL/kg/h.<sup>(<xref rid="r14" ref-type="bibr">14</xref>)</sup></p><p>In the setting of HCPS, Seitsonen et al. reported two cases caused by Puumala virus
infection that rapidly resolved after initiation of corticosteroid treatment
combined with continuous veno-venous hemo-diafiltration.<sup>(<xref rid="r15" ref-type="bibr">15</xref>)</sup> As the use of steroids has not been shown to
provide significant clinical benefit in a number of patients,<sup>(<xref rid="r1" ref-type="bibr">1</xref>)</sup> these cases reinforce the potential
role that HVHF may play as an alternative way of modulating the inflammatory
response in refractory shock in the context of HCPS before proceeding to ECMO.</p><p>Our patient fulfilled the criteria for ECMO due to the presence of refractory shock
despite high doses of norepinephrine, hyperlactatemia and tissue hypoperfusion.
However, hypoxemia was moderate, and the hemodynamic profile resembled that of
severe septic shock. Therefore, based on our extensive experience with HVHF, we
decided to initiate a trial of HVHF.<sup>(<xref rid="r7" ref-type="bibr">7</xref>-<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r16" ref-type="bibr">16</xref>)</sup> The dramatic decrease in norepinephrine
requirements soon after HVHF suggests that this therapy may have played a
significant role in improving the patient's condition. However, whether this was due
to the removal of inflammatory mediators, a decrease in fever or the normalization
of pH remains unclear. If the patient had not responded well to HVHF therapy or
presented with refractory hypoxemia, ECMO would have being started immediately.</p><p>We also cannot exclude the role of Hantavirus hyperimmune plasma in reversing shock.
However, the temporal course suggests otherwise as the patient was already on HVHF
and improving when the hyperimmune plasma was administered. The use of neutralizing
antibodies produced by a DNA vaccine has been shown to protect against lethal ANDV
infection in Syrian hamsters, an animal model of ANDV infection.<sup>(<xref rid="r17" ref-type="bibr">17</xref>)</sup> A non-randomized pilot study in
patients with ANDV infection was conducted in Chile. The results were promising,
with a reduction in mortality from 32% to 14%, compared with the outcomes of
patients from centers that did not participate in the study.<sup>(<xref rid="r10" ref-type="bibr">10</xref>)</sup> However, future studies are
needed to support a definitive recommendation regarding the use of immune
plasma.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>In summary, we describe a patient with Hantavirus cardiopulmonary syndrome who
presented with respiratory failure and severe cardiovascular dysfunction. Despite
fulfilling traditional criteria for extracorporeal membrane oxygenation, the
implementation of high-volume continuous hemofiltration was associated with rapid
shock reversal and may have prompted recovery. In patients with Hantavirus
cardiopulmonary syndrome and cardiovascular dysfunction, we suggest that a 6 to 12
hour trial of high volume continuous hemofiltration be attempted before proceeding
to a more aggressive approach, such as extracorporeal membrane oxygenation. However,
further clinical trials are required to support a definitive recommendation
regarding the use of high volume continuous hemofiltration in these patients.</p></sec></body><back><fn-group><fn fn-type="other"><p><bold>Responsible editor:</bold> Thiago Costa Lisboa</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vial</surname><given-names>PA</given-names></name><name><surname>Valdivieso</surname><given-names>F</given-names></name><name><surname>Ferres</surname><given-names>M</given-names></name><name><surname>Riquelme</surname><given-names>R</given-names></name><name><surname>Rioseco</surname><given-names>ML</given-names></name><name><surname>Calvo</surname><given-names>M</given-names></name><name><surname>Castillo</surname><given-names>C</given-names></name><name><surname>D&#x000ed;az</surname><given-names>R</given-names></name><name><surname>Scholz</surname><given-names>L</given-names></name><name><surname>Cuiza</surname><given-names>A</given-names></name><name><surname>Belmar</surname><given-names>E</given-names></name><name><surname>Hernandez</surname><given-names>C</given-names></name><name><surname>Martinez</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Mertz</surname><given-names>GJ</given-names></name><collab>Hantavirus Study Group in Chile</collab></person-group><article-title>High-dose intravenous methylprednisolone for hantavirus
cardiopulmonary syndrome in Chile: a double-blind, randomized controlled
clinical trial</article-title><source>Clin Infect Dis</source><year>2013</year><volume>57</volume><issue>7</issue><fpage>943</fpage><lpage>951</lpage><pub-id pub-id-type="pmid">23784924</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonsson</surname><given-names>CB</given-names></name><name><surname>Hooper</surname><given-names>J</given-names></name><name><surname>Mertz</surname><given-names>G</given-names></name></person-group><article-title>Treatment of hantavirus pulmonary syndrome</article-title><source>Antiviral Res</source><year>2008</year><volume>78</volume><issue>1</issue><fpage>162</fpage><lpage>169</lpage><comment>Review</comment><pub-id pub-id-type="pmid">18093668</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mertz</surname><given-names>GJ</given-names></name><name><surname>Miedzinski</surname><given-names>L</given-names></name><name><surname>Goade</surname><given-names>D</given-names></name><name><surname>Pavia</surname><given-names>AT</given-names></name><name><surname>Hjelle</surname><given-names>B</given-names></name><name><surname>Hansbarger</surname><given-names>CO</given-names></name><name><surname>Levy</surname><given-names>H</given-names></name><name><surname>Koster</surname><given-names>FT</given-names></name><name><surname>Baum</surname><given-names>K</given-names></name><name><surname>Lindemulder</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Riser</surname><given-names>L</given-names></name><name><surname>Fernandez</surname><given-names>H</given-names></name><name><surname>Whitley</surname><given-names>RJ</given-names></name><collab>Collaborative Antiviral Study Group</collab></person-group><article-title>Placebo-controlled, double-blind trial of intravenous ribavirin
for the treatment of hantavirus cardiopulmonary syndrome in North
America</article-title><source>Clin Infect Dis</source><year>2004</year><volume>39</volume><issue>9</issue><fpage>1307</fpage><lpage>1313</lpage><pub-id pub-id-type="pmid">15494907</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crowley</surname><given-names>MR</given-names></name><name><surname>Katz</surname><given-names>RW</given-names></name><name><surname>Kessler</surname><given-names>R</given-names></name><name><surname>Simpson</surname><given-names>SQ</given-names></name><name><surname>Levy</surname><given-names>H</given-names></name><name><surname>Hallin</surname><given-names>GW</given-names></name><etal/></person-group><article-title>Successful treatment of adults with severe Hantavirus pulmonary
syndrome with extracorporeal membrane oxygenation</article-title><source>Crit Care Med</source><year>1998</year><volume>26</volume><issue>2</issue><fpage>409</fpage><lpage>414</lpage><pub-id pub-id-type="pmid">9468181</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wernly</surname><given-names>JA</given-names></name><name><surname>Dietl</surname><given-names>CA</given-names></name><name><surname>Tabe</surname><given-names>CE</given-names></name><name><surname>Pett</surname><given-names>SB</given-names></name><name><surname>Crandall</surname><given-names>C</given-names></name><name><surname>Milligan</surname><given-names>K</given-names></name><etal/></person-group><article-title>Extracorporeal membrane oxygenation support improves survival of
patients with Hantavirus cardiopulmonary syndrome refractory to medical
treatment</article-title><source>Eur J Cardiothorac Surg</source><year>2011</year><volume>40</volume><issue>6</issue><fpage>1334</fpage><lpage>1340</lpage><pub-id pub-id-type="pmid">21900022</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreno</surname><given-names>MS</given-names></name><name><surname>Castel&#x000e3;o</surname><given-names>RC</given-names></name><name><surname>Braga</surname><given-names>RT</given-names></name><name><surname>Lobo</surname><given-names>SM</given-names></name></person-group><article-title>Hantavirus pulmonary syndrome with multiple organ dysfunctions:
case report</article-title><source>Rev Bras Ter Intensiva</source><year>2007</year><volume>19</volume><issue>4</issue><fpage>494</fpage><lpage>498</lpage><comment>Portuguese</comment><pub-id pub-id-type="pmid">25310170</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cornejo</surname><given-names>R</given-names></name><name><surname>Downey</surname><given-names>P</given-names></name><name><surname>Castro</surname><given-names>R</given-names></name><name><surname>Romero</surname><given-names>C</given-names></name><name><surname>Regueira</surname><given-names>T</given-names></name><name><surname>Vega</surname><given-names>J</given-names></name><etal/></person-group><article-title>High-volume hemofiltration as salvage therapy in severe
hyperdynamic septic shock</article-title><source>Intensive Care Med</source><year>2006</year><volume>32</volume><issue>5</issue><fpage>713</fpage><lpage>722</lpage><pub-id pub-id-type="pmid">16550372</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castro</surname><given-names>R</given-names></name><name><surname>Regueira</surname><given-names>T</given-names></name><name><surname>Aguirre</surname><given-names>ML</given-names></name><name><surname>Llanos</surname><given-names>OP</given-names></name><name><surname>Bruhn</surname><given-names>A</given-names></name><name><surname>Bugedo</surname><given-names>G</given-names></name><etal/></person-group><article-title>An evidence-based resuscitation algorithm applied from the
emergency room to the ICU improves survival of severe septic
shock</article-title><source>Minerva Anestesiol</source><year>2008</year><volume>74</volume><issue>6</issue><fpage>223</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">18356807</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruiz</surname><given-names>C</given-names></name><name><surname>Hernandez</surname><given-names>G</given-names></name><name><surname>Godoy</surname><given-names>C</given-names></name><name><surname>Downey</surname><given-names>P</given-names></name><name><surname>Andresen</surname><given-names>M</given-names></name><name><surname>Bruhn</surname><given-names>A</given-names></name></person-group><article-title>Sublingual microcirculatory changes during high-volume
hemofiltration in hyperdynamic septic shock patients</article-title><source>Crit Care</source><year>2010</year><volume>14</volume><issue>5</issue><fpage>R170</fpage><lpage>R170</lpage><pub-id pub-id-type="pmid">20875109</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vial</surname><given-names>PA</given-names></name><name><surname>Valdivieso</surname><given-names>F</given-names></name><name><surname>Calvo</surname><given-names>M</given-names></name><name><surname>Rioseco</surname><given-names>ML</given-names></name><name><surname>Riquelme</surname><given-names>R</given-names></name><name><surname>Araneda</surname><given-names>A</given-names></name><name><surname>Tomicic</surname><given-names>V</given-names></name><name><surname>Graf</surname><given-names>J</given-names></name><name><surname>Paredes</surname><given-names>L</given-names></name><name><surname>Florenzano</surname><given-names>M</given-names></name><name><surname>Bidart</surname><given-names>T</given-names></name><name><surname>Cuiza</surname><given-names>A</given-names></name><name><surname>Marco</surname><given-names>C</given-names></name><name><surname>Hjelle</surname><given-names>B</given-names></name><name><surname>Ye</surname><given-names>C</given-names></name><name><surname>Hanfelt-Goade</surname><given-names>D</given-names></name><name><surname>Vial</surname><given-names>C</given-names></name><name><surname>Rivera</surname><given-names>JC</given-names></name><name><surname>Delgado</surname><given-names>I</given-names></name><name><surname>Mertz</surname><given-names>GJ</given-names></name><collab>Hantavirus Study Group in Chile</collab></person-group><article-title>A non-randomized multicentre trial of human immune plasma for
treatment of hantavirus cardiopulmonary syndrome caused by Andes
virus</article-title><source>Antivir Ther</source><year>2015</year><volume>20</volume><issue>4</issue><fpage>377</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">25316807</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amato</surname><given-names>MB</given-names></name><name><surname>Carvalho</surname><given-names>CR</given-names></name><name><surname>Vieira</surname><given-names>S</given-names></name><name><surname>Isola</surname><given-names>A</given-names></name><name><surname>Rotman</surname><given-names>V</given-names></name><name><surname>Moock</surname><given-names>M</given-names></name><etal/></person-group><article-title>Mechanical ventilation in the acute lung injury/acute respiratory
distress syndrome</article-title><source>Rev Bras Ter Intensiva</source><year>2007</year><volume>19</volume><issue>3</issue><fpage>374</fpage><lpage>383</lpage><comment>Portuguese</comment><pub-id pub-id-type="pmid">25310077</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bugedo</surname><given-names>G</given-names></name><name><surname>Bruhn</surname><given-names>A</given-names></name><name><surname>Regueira</surname><given-names>T</given-names></name><name><surname>Romero</surname><given-names>C</given-names></name><name><surname>Retamal</surname><given-names>J</given-names></name><name><surname>Hern&#x000e1;ndez</surname><given-names>G</given-names></name></person-group><article-title>Positive end-expiratory pressure increases strain in patients
with ALI/ARDS</article-title><source>Rev Bras Ter Intensiva</source><year>2012</year><volume>24</volume><issue>1</issue><fpage>43</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">23917712</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honore</surname><given-names>PM</given-names></name><name><surname>Jamez</surname><given-names>J</given-names></name><name><surname>Wauthier</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>PA</given-names></name><name><surname>Dugernier</surname><given-names>T</given-names></name><name><surname>Pirenne</surname><given-names>B</given-names></name><etal/></person-group><article-title>Prospective evaluation of short-term, high-volume isovolemic
hemofiltration on the hemodynamic course and outcome in patients with
intractable circulatory failure resulting from septic shock</article-title><source>Crit Care Med</source><year>2000</year><volume>28</volume><issue>11</issue><fpage>3581</fpage><lpage>3587</lpage><pub-id pub-id-type="pmid">11098957</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joannes-Boyau</surname><given-names>O</given-names></name><name><surname>Honor&#x000e9;</surname><given-names>PM</given-names></name><name><surname>Perez</surname><given-names>P</given-names></name><name><surname>Bagshaw</surname><given-names>SM</given-names></name><name><surname>Grand</surname><given-names>H</given-names></name><name><surname>Canivet</surname><given-names>JL</given-names></name><etal/></person-group><article-title>High-volume versus standard-volume haemofiltration for septic
shock patients with acute kidney injury (IVOIRE study): a multicentre
randomized controlled trial</article-title><source>Intensive Care Med</source><year>2013</year><volume>39</volume><issue>9</issue><fpage>1535</fpage><lpage>1546</lpage><pub-id pub-id-type="pmid">23740278</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seitsonen</surname><given-names>E</given-names></name><name><surname>Hynninen</surname><given-names>M</given-names></name><name><surname>Kolho</surname><given-names>E</given-names></name><name><surname>Kallio-Kokko</surname><given-names>H</given-names></name><name><surname>Pettil&#x000e4;</surname><given-names>V</given-names></name></person-group><article-title>Corticosteroids combined with continuous veno-venous
hemodiafiltration for treatment of hantavirus pulmonary syndrome caused by
Puumala virus infection</article-title><source>Eur J Clin Microbiol Infect Dis</source><year>2006</year><volume>25</volume><issue>4</issue><fpage>261</fpage><lpage>266</lpage><pub-id pub-id-type="pmid">16550348</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rimmel&#x000e9;</surname><given-names>T</given-names></name><name><surname>Kellum</surname><given-names>JA</given-names></name></person-group><article-title>High-volume hemofiltration in the intensive care unit: a blood
purification therapy</article-title><source>Anesthesiology</source><year>2012</year><volume>116</volume><issue>6</issue><fpage>1377</fpage><lpage>1387</lpage><pub-id pub-id-type="pmid">22534247</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hooper</surname><given-names>JW</given-names></name><name><surname>Ferro</surname><given-names>AM</given-names></name><name><surname>Wahl-Jensen</surname><given-names>V</given-names></name></person-group><article-title>Immune serum produced by DNA vaccination protects hamsters
against lethal respiratory challenge with Andes virus</article-title><source>J Virol</source><year>2008</year><volume>82</volume><issue>3</issue><fpage>1332</fpage><lpage>1338</lpage><pub-id pub-id-type="pmid">18032485</pub-id></element-citation></ref></ref-list></back></article>